US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5
variant
Send a link to a friend
[June 19, 2023]
(Reuters) - The U.S. Food and Drug Administration (FDA) said on
Friday it has advised manufacturers that are updating their COVID-19
vaccines to develop monovalent shots to target the XBB.1.5 subvariant.
So-called monovalent, or single-target vaccines, would be a change from
the most recent bivalent COVID boosters that targeted both the original
and Omicron strains of the coronavirus.
The FDA's advice comes a day after its panel of experts unanimously
recommended that the updated COVID shots being developed for a fall
vaccination campaign target one of the currently dominant XBB
coronavirus variants.
COVID vaccine makers Pfizer/BioNTech, Moderna and Novavax are already
developing versions of their respective vaccines to target XBB.1.5 and
other currently circulating subvariants.
[to top of second column]
|
A woman holds a small bottle labelled
with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe
in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File
Photo
Novavax's XBB.1.5 COVID vaccine
candidate is being manufactured at commercial scale, with plans for
it to be in the market for the fall campaign, the company said on
Friday.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Pooja Desai)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |